Similar articles for PMID: 32345669

Year	Number of Results
1993	1
2003	1
2006	1
2008	1
2009	3
2010	4
2011	6
2012	4
2013	10
2014	10
2015	8
2016	15
2017	11
2018	6
2019	7
2020	4
2022	1
2024	0

1

Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.

Pectasides E, Chatzidakis I, Kotoula V, Koliou GA, Papadopoulou K, Giannoulatou E, Giannouzakos VG, Bobos M, Papavasileiou C, Chrisafi S, Florou A, Pectasides D, Fountzilas G. Pectasides E, et al. Cancer Genomics Proteomics. 2020 May-Jun;17(3):277-290. doi: 10.21873/cgp.20188. Cancer Genomics Proteomics. 2020. PMID: 32345669 Free PMC article.

2

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

Petrini I, Lencioni M, Vasile E, Fornaro L, Belluomini L, Pasquini G, Ginocchi L, Caparello C, Musettini G, Vivaldi C, Caponi S, Ricci S, Proietti A, Fontanini G, Naccarato AG, Nardini V, Santi S, Falcone A. Petrini I, et al. Cancer Biomark. 2018 Feb 14;21(3):731-741. doi: 10.3233/CBM-170865. Cancer Biomark. 2018. PMID: 29278885

3

KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz RD. Erben P, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1032-8. doi: 10.1016/j.ijrobp.2010.06.043. Epub 2010 Oct 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 20947270 Clinical Trial.

4

HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.

Park JS, Yoon G, Kim HJ, Park SY, Choi GS, Kang MK, Kim JG, Jang JS, Seo AN. Park JS, et al. Virchows Arch. 2018 Oct;473(4):413-423. doi: 10.1007/s00428-018-2409-y. Epub 2018 Jul 28. Virchows Arch. 2018. PMID: 30056472

5

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD. Kadota K, et al. Am J Surg Pathol. 2016 Dec;40(12):1579-1590. doi: 10.1097/PAS.0000000000000744. Am J Surg Pathol. 2016. PMID: 27740967 Free PMC article.

6

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Taylor M, Bottomley D, Chambers P, Lawrie E, Lopes A, Beare S. Gollins S, et al. Br J Cancer. 2017 Oct 24;117(9):1286-1294. doi: 10.1038/bjc.2017.294. Epub 2017 Aug 31. Br J Cancer. 2017. PMID: 28859058 Free PMC article. Clinical Trial.

7

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R. Bettstetter M, et al. Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14. Hum Pathol. 2013. PMID: 23158210

8

Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.

Hedner C, Borg D, Nodin B, Karnevi E, Jirström K, Eberhard J. Hedner C, et al. J Clin Pathol. 2018 May;71(5):451-462. doi: 10.1136/jclinpath-2017-204774. Epub 2017 Nov 14. J Clin Pathol. 2018. PMID: 29138285

9

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Abubaker J, et al. J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625. J Pathol. 2009. PMID: 19824059

10

Gastric cancer and concomitant renal cancer: a systematic immunohistochemical and molecular analysis.

Betge J, Pollheimer MJ, Schlemmer A, Hoefler G, Langner C. Betge J, et al. Oncol Rep. 2011 Sep;26(3):567-75. doi: 10.3892/or.2011.1346. Epub 2011 Jun 15. Oncol Rep. 2011. PMID: 21687951

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

78 results

Results by year